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The cryoprotectant, Dimethyl sulfoxide (DMSO) is known to
have toxic side effects in stem cell transplantation. The
overall incidence of DMSO toxicity was approximately one in
70 transplants. The mean incidence of DMSO toxicity per
center was 2.1%, when 34,000 transplants had been carried
out by 95 centers. DMSO exhibits acute mortality at doses of
30 e 40 mg/kg in animals, and fatal arrhythmias, respiratory
arrest with diffuse alveolar hemorrhage, seizures, leu-
koencephalopathy and hemoglobinuria in humans. In light of
this, DMSO dose levels per day should be evaluated and
certain cutoffs should be mandated for patients' safety.
In order to assess risks of toxicity, our center documented the
retained plasma levels of DMSO in two patients that were
scheduled to receive in excess of 6 bags of autologous units.
Standard practice at our institution is to add 10% DMSO per
100 ml bag for cryoprotectant. Each 100 ml bag has 50 ml
cells plus 50 ml freeze solution (50% freeze solution ¼ 20%
DMSO + 2% heprin + 78% plasmalyte A). Both patients
received 6 bags of stem cells on day 1, followed by plasma
determination of DMSO. Repeated levels were obtained prior
to and following second day of infusion of autologous units.
Under gas chromatography, plasma DMSO2 concentration
increased during ﬁrst 24 hrs, plateaued at 4.4 +/- 1.2 mmol/L
and remained there for 48 hrs. DMSH2 concentrations were
at steady state by 5min and remained between 3e 5mmol/L
for 48 hrs. Renal clearance of DMSO was 14.1 +/- 3.4 ml/min.
The DMSO dose used and the plasma clearance rates in two
different patients are shown in the graphs below.Based on
DMSO clearance rates one would expect clearance of DMSO
to be higher than what was clinically found. We believe, this
highlights the importance of other factors that can decrease
DMSO clearance rates during stem cell transplant. For this
reason, limit setting of 100 mg of DMSO per day would be
a reasonable to avoid increased levels of toxicity. Based on
this algorithm, our center has mandated no more than 6Figure 1.autologous units be infused per day (SOP 117 OU Medical
Center).410
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Background: The outcome for children and adolescents with
B-L/L has improved signiﬁcantly but for patients who relapse
or progress, the prognosis is dismal due to chemo-immuno-
radiotherapy resistance (Cairo, J Clin Oncol, 2012). Novel
therapies are desperately needed for this speciﬁc poor risk
population. Natural Killer (NK) cells play an important role in
tumor surveillance post allogeneic stem cell transplantation
(Ruggeri, Science 2002) but cell number and tumor speciﬁc
recognition limit adoptive NK cell therapy (Shereck/Cairo,
PBC 2007). Histone Deacetylase Inhibitors (HDACi) represent
a new class of anti-tumor agents. They also up-regulate the
expression of NKG2D ligands such as MICA/B (Satwani/Cairo,
ASBMT 2009).
Objective: We investigated 1) functional activities of anti-
CD20 CAR modiﬁed PBNK cells following mRNA nucleo-
fection against CD20+ B-L/L and 2) the combined effect of
CAR+ PBNK cells with Romidepsin against B-L/L cells.
Methods: PBMC were expanded with inactivated K562-
mbIL15-41BBL cells for 7 days. Expanded CD56+CD3- PBNK
(exPBNK) cells were isolated. Anti-CD20-4-1BB-CD3z mRNA
(CAR mRNA) was produced in vitro and nucleofected into
exPBNK. CAR expression was detected using speciﬁc anti-
body by ﬂow cytometry. exPBNK cytotoxicity was assessed
by europium release assay. Intracellular CD107a degranula-
tion in exPBNK was measured by ﬂow cytometry. CD20+
Ramos and CD20dim NALM-6 cells were treatedwith 10ng/ml
Romidepsin, provided by Celgene. MICA/B and CD20
expression were analyzed by ﬂow cytometry.
Results: exPBNK cells were selected with more than 96%
purity. 50 to 95% exPBNK cells were detected to express CAR
at 16 hrs after CAR mRNA nucleofection.
exPBNK in vitro cytotoxicity was signiﬁcantly enhanced by
CAR+ exPBNK compared to CAR- exPBNK against CD20+
Ramos (P < .05), Daudi, Raji, two Rituximab resistant cell
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signiﬁcant difference against CD20- control cells: RS4;11 and
Jurkat.
Consistently, intracellular CD107a degranulation was
enhanced in CAR+ exPBNK compared to CAR- exPBNK in
response to CD20+ Ramos.
MIC expressionwas signiﬁcantly increased in Ramos (P< .05)
and in NALM-6 (P < .001) after romidepsin treatment.
CD20 expression was signiﬁcantly increased in NALM-6 (P <
.001) after romidepsin treatment.
CAR+ exPBNK in vitro cytotoxicity was signiﬁcantly enhanced
against romidepsin treated Ramos (P< .02) and NALM-6 (P<
.01) compared to untreated targets.
Conclusion: Anti-CD20 CAR expression in exPBNK cells
results in signiﬁcant and speciﬁc in vitro cytotoxicity against
CD20+ B-L/L. Romidepsin increases MICA/B and CD20
expression in B-L/L. CAR exPBNK signiﬁcantly enhanced
cytotoxicity against romidepsin treated B-L/L. Future direc-
tions include examining the combination effect of CAR
exPBNK and Romidepsin against B-L/L in xenograft mice.411
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T cell depletion (TCD) by negative or positive selection
reduces graft-vs-host disease and its complications while
maintaining relapse free survival in appropriately selected
patients. Differences in acute GVHD incidence of sibling
donor transplants using 3 TCDmethods stimulated review of
graft content. Graft source (bone marrow [BM] or peripheral
blood stem cells [PBSC]) and TCD method determine cell
composition, impacting outcome and survival. As a center
historically committed to TCD, we reviewed 531 TCD grafts
processed in 2000-2011 using 3 TCD methods for BM or
PBSC. Pre and postprocessing cell composition, log10 TCD,
and % CD34+ recovery were compared. BM, negatively
selected by soybean lectin agglutination and sheep RBC
rosetting (SBA-E-) was used in 76 patients; PBSC, positively
selected for CD34+ cells by the Isolex followed by RBCTable
Median Cell Dose/kg Pre and Post TCD
Cells TNC CD34 CD3
Pre BM 3.81E+08 5.87E+06 2.69E+07
Pre PBSC 1.19E+09 8.72E+06 2.38E+08
SBA-E- 2.84E+07 1.86E+06 6.07E+04
Iso E- 7.63E+06 7.31E+06 1.58E+03
Clini 8.53E+06 1.05E+07 3.56E+03rosetting (IsoE-) for 361 patients, or by the CliniMACS (Clini),
for 94 patients. The table shows preprocessing cell doses and
phenotypic proﬁle were signiﬁcantly different between pre
BM and pre PBSC for TNC, CD3+T cells, T cell subsets, NK cells
and CD34+ (P-values < .001, Wilcoxon rank-sum test). BM T
cells had a 1:1 ratio of CD4:CD8 while PBSC had a 1:2 ratio.
The table shows post TCD T cell doses were signiﬁcantly
higher in BM than in PBSC grafts. In TCD BM, the median log
10 depletion of CD3 + T cells (2.65) was signiﬁcantly different
from IsoE log10 TCD (5.22). Clini log 10 TCD (4.92) was
similar to IsoE. Strikingly, while preprocessed BM had fewer
NK CD56/16+ than PBSC (3.86E+06 vs. 3.59E+07), the nega-
tive selection of BM left more NK cells in the TCD graft,
resulting in signiﬁcantly higher NK cell dose (6.73E+05) than
after CD34+ positive selection by Iso E- (2.25E+03) or Clini
(6.98E+02). IsoE- had signiﬁcantly (P < .001) higher CD34
doses (7.31E+06 /kg) and greater recovery (85.0%) of CD34+
cells; than SBA-E- (1.86E+06 /kg, 33.3% recovery). Clini
selection resulted in similar CD34 cell doses and recovery to
the IsoE-. (1.05E+07/kg, 116.74 % recovery). Number and
types of CD3+ T cells, T subpopulations, NK, and CD34+ in
TCD grafts act in concert with donor and host parameters to
effect ﬁnal transplant outcome. Characterization of cells in
preprocessed grafts and retained by TCDmethods can lead to
better graft engineering and optimization of the cellular
content of the ﬁnal T depleted product.412
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T cell depletion (TCD) by negative or positive selection
reduces graft-vs-host disease and its complications while
maintaining relapse free survival in appropriately selected
patients. Differences in acute GVHD incidence of sibling
donor transplants using 3 TCDmethods stimulated review of
graft content. Graft source (bone marrow [BM] or peripheral
blood stem cells [PBSC]) and TCD method determine cell
composition, impacting outcome and survival. As a center
historically committed to TCD, we reviewed 531 TCD grafts
processed in 2000-2011 using 3 TCD methods for BM or
PBSC. Pre and postprocessing cell composition, log10 TCD,
and % CD34+ recovery were compared. BM, negatively
selected by soybean lectin agglutination and sheep RBC
rosetting (SBA-E-) was used in 76 patients; PBSC, positively
selected for CD34+ cells by the Isolex followed by RBC
rosetting (IsoE-) for 361 patients, or by the CliniMACS (Clini),
for 94 patients. The table shows preprocessing cell doses and
phenotypic proﬁle were signiﬁcantly different between pre
BM and pre PBSC for TNC, CD3+T cells, T cell subsets, NK cells
and CD34+ (P-values < .001, Wilcoxon rank-sum test). BMCD4 CD8 TCR gd CD56/16
1.32E+07 1.27E+07 1.26E+06 3.86E+06
1.37E+08 2.59E+08 9.71E+06 3.59E+07
8.30E+03 4.04E+04 1.20E+04 6.73E+05
3.88E+02 7.78E+02 <1.00E+02 2.25E+03
2.06E+03 1.49E+03 <1.00E+02 6.98E+02
